The primary definition of SN‐APS turned into, given in 2003 by Hughes and Khamashta, who described patients with medical manifestations incredibly suggestive of APS in absence of the laboratory standards inclusive of lupus anticoagulant (LAC), anti‐cardiolipin (aCL), and beta 2 glycoprotein (β2GPI) antibodies [1, 2]. The gene discussed is ACLY; the disease is autoimmune polyendocrinopathy.